Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

130.44 +2.97 (+2.33%)

Streaming Delayed Price Updated: 2:21 PM EDT, Jul 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

July 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

July 16, 2026

From Merck & Co., Inc.

Via Business Wire

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

July 15, 2026

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

July 15, 2026

From Merck & Co., Inc.

Via Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

July 10, 2026

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

July 01, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

June 29, 2026

From Merck & Co., Inc.

Via Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

June 25, 2026

From Merck & Co., Inc.

Via Business Wire

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

June 24, 2026

Via Investor Brand Network

The Quest to Repair What Multiple Sclerosis Takes Away

June 24, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

June 24, 2026

Via Investor Brand Network

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies

June 24, 2026

Via Investor Brand Network

Topics Artificial Intelligence

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

June 24, 2026

From Merck & Co., Inc.

Via Business Wire

The Quest to Repair What Multiple Sclerosis Takes Away

June 24, 2026

From BioMedWire

Via GlobeNewswire

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

June 22, 2026

From Merck & Co., Inc.

Via Business Wire

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

June 24, 2026

From BioMedWire

Via GlobeNewswire

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

June 18, 2026

From Merck & Co., Inc.

Via Business Wire

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

June 17, 2026

From Merck & Co., Inc.

Via Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

June 12, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Animal Health to Acquire TARGAN

June 11, 2026

From Merck & Co., Inc.

Via Business Wire

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

June 08, 2026

From Gilead Sciences, Inc.

Via Business Wire

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

June 08, 2026

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 02, 2026

From Merck & Co., Inc.

Via Business Wire

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

June 01, 2026

Via ACCESS Newswire

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

May 29, 2026

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Announces Third-Quarter 2026 Dividend

May 26, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

May 22, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

May 18, 2026

From Merck & Co., Inc.

Via Business Wire

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

Via Investor Brand Network

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.